MetaCap

Profound Medical Corp. (PROF)

NASDAQ: PROFHealth CareMedical/Dental InstrumentsUSD

6.38-0.21 (-3.19%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PROF stock chart

Technical analysis

Key statistics

All statistics
Market cap
$233.68M
EPS (TTM)
-$0.94
52-week range
4.80 – 8.95
Day range
6.26 – 6.65
Volume / Avg
144.19K / 208.29K
Beta
—

52-week range

$4.80$8.95

PROF stock today

Profound Medical (PROF) closed at $6.38 on Nov 20, down 3.19% (-$0.21), versus the S&P 500's 3.70% decline. Shares are 28.7% below their 52-week high of $8.95, set on Jan 13, 2026 and 32.9% above the 52-week low of $4.80, in the middle of the past year's range. PROF is down 18.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 6.2%.

Profound Medical has posted a net loss over the last twelve months (EPS of -$0.94), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Profound Medical

Company profile

Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue.

Industry
Medical/Dental Instruments
CEO
Dr. Arun Swarup Menawat MBA, Ph.D.
Headquarters
Mississauga, ON
Employees
162

Financial highlights

Full financials

In fiscal 2025, Profound Medical generated $16.1 million in revenue, up 50.7% from fiscal 2024, its 3rd consecutive year of revenue growth. Profound Medical reported a net loss of $42.6 million, compared with a loss of $27.8 million a year earlier. Gross margin was 70.8% (up from 65.9%) and operating margin -256.3%.

Profound Medical annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$16.10M$10.68M$7.20M$6.68M$6.87M
Growth+50.73%+48.35%+7.75%-2.79%-5.90%
Net income$-42.57M$-27.82M$-28.32M$-28.67M$-30.70M
EPS (diluted)$1.41$1.12$1.34$1.38$1.50

Analyst forecast

Forecast

Consensus (5 analysts)

strong_buy

Avg. price target

$11.14+74.61%

  • Strong buy 0
  • Buy 5
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $10.00High $12.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.21 vs $-0.19
Surprise
-10.53%

PROF news

All PROF news

Profound Medical peers

Health Care sector
PROF peer companies
CompanyPrice% ChgMarket capCompare
OSUROraSure Technologies Inc.3.46-4.16%$238.90Mvs PROF
CLPTClearPoint Neuro Inc.6.91-5.47%$221.49Mvs PROF
OFIXOrthofix Medical Inc.6.07-4.26%$247.41Mvs PROF
SSIISS Innovations International Inc.1.27-0.78%$254.86Mvs PROF
KTWOK2 Capital Acquisition Corporation Class A10.130.00%$203.02Mvs PROF
PDEXPro-Dex Inc.63.00-0.77%$201.60Mvs PROF
UTMDUtah Medical Products Inc.69.49-2.07%$198.01Mvs PROF
NPCENeuropace Inc.7.95-2.33%$273.89Mvs PROF

Indexes, lists and sector

Profound Medical stock FAQ

What is Profound Medical's stock price today?

PROF last traded at $6.38 as of Nov 20, 4:00 PM EST, down 3.19% on the day. Prices are delayed at least 15 minutes.

Who is Profound Medical's CEO?

Dr. Arun Swarup Menawat MBA, Ph.D. is the chief executive officer of Profound Medical Corp., which has about 162 employees.

What is the PROF 52-week high?

The 52-week high for PROF is $8.95 and the 52-week low is $4.80. The stock is currently 28.7% below its high.

Compare PROF